WESTBOROUGH, Mass.,
Feb. 3, 2014 /PRNewswire/ --
RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology
company focused on discovering, developing and commercializing
innovative therapies addressing major unmet medical needs using
RNA-targeted technologies, today announced that the Company's
President & CEO, Dr. Geert
Cauwenbergh, will present at the 16th Annual
BIO CEO & Investor Conference on
Tuesday, February 11, 2014 at
11:30am EST. Dr. Cauwenbergh
will discuss the development of RXI-109, a self-delivering RNAi
compound designed to reduce dermal scarring, as well as business
development opportunities with RXi's sd-rxRNA® technology
platform.
(Logo:
http://photos.prnewswire.com/prnh/20130917/NE80755LOGO)
The presentation will be available on the "Investors" section of
the Company's website, www.rxipharma.com.
The 16th Annual BIO
CEO & Investor Conference is the largest independent
investor conference focused on publicly-traded biotechnology
companies. The conference is designed to foster an
informative dialogue between institutional investors and senior
biotechnology executives about emerging and current investment
opportunities. The conference will take place February 10-11 at the Waldorf Astoria in New York
City.
About RXi Pharmaceuticals Corporation
RXi Pharmaceuticals Corporation (OTCQX: RXII) is a biotechnology
company focused on discovering, developing and commercializing
innovative therapies based on its proprietary, self-delivering RNAi
platform. Therapeutics that use RNA interference, or "RNAi," have
great promise because of their ability to down-regulate the
expression of a specific gene that may be over-expressed in a
disease condition. Building on the pioneering work of scientific
founder and Nobel Laureate Dr. Craig
Mello, a member of the RXi Scientific Advisory Board, RXi's
first RNAi product candidate, RXI‑109, targets connective tissue
growth factor (CTGF) to reduce dermal scarring (fibrosis), entered
into human clinical trials in June 2012. For more
information, please visit www.rxipharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Such statements include, but are not limited to, statements
about future expectations, planned and future development of RXi
Pharmaceuticals Corporation's products and technologies.
Forward-looking statements about expectations and development plans
of RXi's products involve significant risks, and uncertainties:
risks that RXi may not be able to successfully develop its
candidates, or that development of RNAi-based therapeutics may be
delayed or not proceed as planned, or that we may not develop any
RNAi-based product; risks that the development process for our
product candidates may be delayed, risks related to development and
commercialization of products by our competitors, risks related to
our ability to control timing and terms of collaborations with
third parties, and the possibility that other companies or
organizations may assert patent rights preventing us from
developing our products. Actual results may differ from those
contemplated by these forward-looking statements. RXi does not
undertake to update forward-looking statements to reflect a change
in its views, events or circumstances that occur after the date of
this release.
Contacts
RXi Pharmaceuticals Corporation
Tamara McGrillen, 508-929-3646
tmcgrillen@rxipharma.com
SOURCE RXi Pharmaceuticals Corporation